Literature DB >> 1928557

Chromogranin A and B in adenomas of the pituitary. An immunohistochemical study of 42 cases.

K W Schmid1, M Kröll, A Hittmair, H Maier, M Tötsch, R Gasser, G Finkenstett, R Hogue-Angeletti, R Fischer-Colbrie.   

Abstract

Forty-two pituitary adenomas (10 prolactinomas; three ACTH-, nine GH-, two FSH- and two TSH-secreting adenomas; and 16 clinically nonfunctioning null cell adenomas) were investigated immunohistochemically with antibodies against chromogranin A and B as well as ACTH, GH, prolactin (PRL), FSH, LH, TSH, and alpha-HCG antibodies. For the demonstration of chromogranin B, two different antibodies were used--e.g., a polyclonal antihuman antibody and an antiserum against a synthetic peptide (DK-21, chromogranin B 306-326) present in the chromogranin B amino acid sequence. All tumors were positive for both chromogranin B antibodies. Chromogranin A was found in FSH- (two of two) and TSH- (two of two) secreting adenomas; it was also found in a focal distribution in ACTH- (one of three) and GH- (four of nine) secreting adenomas. Thirteen of 16 null cell adenomas contained chromogranin A, whereas no chromogranin A was found in prolactinomas. We conclude that null cell adenomas may arise either from FSH/LH or TSH cells (null cell adenomas with both chromogranin A and B positivity) or from ACTH, GH, or PRL cells (the respective tumors are only positive for chromogranin B). Chromogranin B may be used as a universal marker for pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928557     DOI: 10.1097/00000478-199111000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in primary non-small-cell carcinomas of the lung.

Authors:  Martin Tötsch; Birgit Kunk; Barbara Dockhorn-Dworniczak; Dietmar Öfner; Reiner Fischer-Colbrie; Gregor Mikuz; Werner Böcker; Kurt Werner Schmid
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

2.  Combined use of 111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin A monoclonal antibody in the diagnosis of pituitary adenomas.

Authors:  P Magnani; G Paganelli; A G Siccardi; C Songini; P Colombo; G Faglia; F Fazio
Journal:  Cell Biophys       Date:  1994

3.  Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors.

Authors:  P Colombo; G Paganelli; P Magnani; C Songini; F Fazio; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

Review 4.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

5.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

6.  Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.

Authors:  Maode Lai; Bingjian Lü; Xiaoming Xing; Enping Xu; Guoping Ren; Qiong Huang
Journal:  Virchows Arch       Date:  2006-09-06       Impact factor: 4.064

7.  Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas.

Authors:  Mamta Gupta; Ricardo V Lloyd; Reiner Fischer-Colbrie; Arthur S Tischler; Yogeshwar Dayal
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

8.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.

Authors:  R V Lloyd; L Jin; X Qian; B W Scheithauer; W F Young; D H Davis
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

10.  Pituitary oncocytoma presenting as Cushing's disease.

Authors:  M K Garg; Reena Bharwaj; H C Pathak; Sandeep Kharb; Abhay Gundgurthi; Aditi Pandit; K S Brar
Journal:  Indian J Endocrinol Metab       Date:  2013-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.